GB Sciences, Inc. (GBLX)

OTCMKTS: GBLX · Delayed Price · USD
0.0065
0.00 (0.00%)
Apr 12, 2024, 10:32 AM EDT - Market open
Market Cap 2.62M
Revenue (ttm) n/a
Net Income (ttm) -6.03M
Shares Out 406.07M
EPS (ttm) -0.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 294,698
Open 0.0066
Previous Close 0.0065
Day's Range 0.0065 - 0.0066
52-Week Range 0.0065 - 0.0200
Beta 0.32
Analysts n/a
Price Target n/a
Earnings Date n/a

About GBLX

GB Sciences, Inc., a phytomedical research and biopharmaceutical drug development company, engages in the research and development of plant-based medicines. The company offers cannabinoid-inspired medicines and complex therapeutic mixtures for the prescription drug market. Its intellectual property covers a range of medical conditions and programs in pre-clinical animal stage for Parkinson's disease, neuropathic pain, chronic pain, COVID-related cytokine release syndrome, depression/anxiety, and cardiovascular therapeutic programs. The company ... [Read more]

Industry Biotechnology
Sector Healthcare
CEO John Claybron Poss
Employees 3
Stock Exchange OTCMKTS
Ticker Symbol GBLX
Full Company Profile

Financial Performance

Financial Statements

News

Gb Sciences Identifies Novel Cannabis-Inspired Mixtures as Anti-Inflammatory Therapies Based on Proprietary AI-Enabled Drug Discovery Platform

Gb Sciences' innovative approach harnesses the power of plant-based treatments as simplified mixtures that target dangerous hyperinflammatory responses to viral infections. Gb Sciences' innovative app...

1 year ago - GlobeNewsWire

Gb Sciences Addresses Growing Need for Anxiety and Depression Medications With Non-Psychedelic, Kava-Based Formulations

As mental health disorders increasingly impact global populations, Gb Sciences is developing psychotropic but non-psychedelic treatments for anxiety and depression that compete with the emerging billi...

1 year ago - GlobeNewsWire

Gb Sciences Co-Publishes Study Demonstrating Anti-Inflammatory Properties of Cannabis Ingredients

As published in the journal Food and Chemical Toxicology, the biopharmaceutical drug development firm's sponsored research used co-cultured human, primary immune cells as a model to evaluate the abili...

1 year ago - GlobeNewsWire

TODAY: Gb Sciences' President Demonstrates Benefits of AI-Enabled Drug Discovery Engine for Novel Plant-Inspired Pharmaceuticals at 10th Annual Drug Discovery Strategic Summit

At the Annual Summit, Dr. Andrea Small-Howard is presenting a Keynote Address that includes data from case studies demonstrating the utility of Gb Sciences' proprietary PhAROS drug discovery platform....

1 year ago - GlobeNewsWire

Gb Sciences' Plant-based Formulations Designed to Treat Anxiety Achieve Statistical Significance in Animal Study

Gb Sciences' anxiety formulations were previously identified using the company's AI-driven PhAROS™ platform, and they have now been evaluated using preclinical zebrafish models of stress at the Nation...

1 year ago - GlobeNewsWire

TODAY: Gb Sciences' President Demonstrates Effectiveness of Simplified Therapeutic Mixtures Inspired by Cannabis Plant Extracts at Canna Pharma 2022 Conference

Dr. Andrea Small-Howard discusses the company's novel process for developing disease-specific, cannabinoid-based therapeutics. Dr. Andrea Small-Howard discusses the company's novel process for develop...

1 year ago - GlobeNewsWire

Gb Sciences Co-Publishes Study Demonstrating Efficacy of Its Proprietary Cannabinoid Mixtures for the Treatment of Parkinson's Disease

As published in Frontiers in Pharmacology, the biopharmaceutical drug development firm's sponsored research has identified and validated cannabinoid ratio-controlled, Minimum Essential Mixtures (MEM) ...

1 year ago - GlobeNewsWire

TODAY: Gb Sciences Describes Drug Development Progress in Pharma's Almanac Journal Article

Gb Sciences is focusing considerable resources on bringing its lead Parkinson's disease formulations to the clinic with promising results; plus, new data validating the efficacy of their novel anxiety...

1 year ago - GlobeNewsWire

Gb Sciences is Leading Digital Transformation in Biopharma Industry Through Its Novel AI-Accelerated Drug Discovery Platform—PhAROS™

As digitization becomes a necessity in the life sciences industry, Gb Sciences proves it's already ahead of the curve with its own revolutionary technology. As digitization becomes a necessity in the ...

1 year ago - GlobeNewsWire

Gb Sciences Leads Digital Transformation in Biopharma Industry Through Its Novel AI-Accelerated Drug Discovery Platform—PhAROS™

As digitization becomes a necessity in the life sciences industry, Gb Sciences proves it's already ahead of the curve with its own revolutionary technology. As digitization becomes a necessity in the ...

1 year ago - GlobeNewsWire

TODAY: Gb Sciences' President and Chief Science Officer Presents Keynote Address on Cannabinoid-Containing Formulations for Parkinson's Disease at 2022 NeuroForum Summit

Dr. Andrea Small-Howard explains that Gb Sciences' multicomponent Parkinson's disease therapeutic addresses this multi-factorial neurodegenerative condition using a combination of cannabinoids that ar...

2 years ago - GlobeNewsWire

TODAY: Gb Sciences Showcases Its PhAROS™ Drug Discovery Platform at the 2nd ALCOR Drug Discovery Platform Summit

President and Chief Science Officer Dr. Andrea Small-Howard demonstrates the platform's utility for predicting novel plant-inspired drug candidates and describes its role in Gb Sciences' future succes...

2 years ago - GlobeNewsWire

TODAY: Gb Sciences' Novel Plant-Inspired Pain Medications Featured at SMi's 22nd Annual Pain Therapeutics Conference

President and Chief Science Officer Dr. Andrea Small-Howard stressed the importance of developing their innovative, plant-inspired formulations as a potentially safer alternative to existing opioid-ba...

2 years ago - GlobeNewsWire

Gb Sciences' Nanoparticle Encapsulation Technology Improves the Efficacy of Terpenes for Use in Our Chronic Pain Formulations as Demonstrated in New Research Article

On March 25, the University of Seville, Chaminade University, and Gb Sciences co-published the results from Gb Sciences-sponsored study in the International Journal of Pharmaceutics. Gb Sciences' prop...

2 years ago - GlobeNewsWire

UPDATE: Gb Sciences Issues Shareholder Letter

Biopharmaceutical research company specializing in cannabis- and plant-inspired medicines shares strategic plan for 2022 and key developments from 2021 Biopharmaceutical research company specializing ...

2 years ago - GlobeNewsWire

Gb Sciences Issues Summary Shareholder Letter

Biopharmaceutical research company specializing in cannabis- and plant-inspired medicines shares strategic plan for 2022 and key developments from 2021 Biopharmaceutical research company specializing ...

2 years ago - GlobeNewsWire

Gb Sciences and Michigan State University Researchers Have Identified the Complicated Truth Behind the Opportunity for an Effective Cannabinoid-Based Coronavirus Treatment

Gb Sciences' collaboration with MSU has received media coverage across the country, starting with an interview from WLNS-TV in Lansing, Michigan, and interviews with Gb Sciences in the magazines 'Cann...

2 years ago - GlobeNewsWire

Gb Sciences Leaves Cannabis Cultivation With $8M Sale Of Las Vegas Facility, Enters BioPharma Industry

Gb Sciences, Inc. (OTCQB:GBLX) announced Tuesday that it has closed the sale of its last remaining cannabis facility, completing a transition to the biopharmaceutical industry. What Happened Based in ...

2 years ago - Benzinga

Gb Sciences Completes $8 Million Sale of Las Vegas Cannabis Facility

The sale will accelerate the development of Gb Sciences' proprietary Parkinson's disease and COVID-related Cytokine-Release Syndrome therapies The sale will accelerate the development of Gb Sciences' ...

2 years ago - GlobeNewsWire

Gb Sciences Starts Preclinical Study for Plant-Based Formulas to Treat Depression and Anxiety

The biopharma technology company's AI-driven PhAROS™ platform has identified novel, plant-inspired formulations that will be tested using preclinical Zebrafish models at the National Research Council ...

2 years ago - GlobeNewsWire

Gb Sciences Achieves Positive Proof-of-Concept Results for Their Cytokine Release Syndrome Therapies Designed to Suppress COVID-Related Hyperinflammation

Based on a recently completed preclinical study performed at Michigan State University, Gb Sciences' preclinical data supports further development of their novel cannabinoid-containing complex mixture...

2 years ago - GlobeNewsWire

Gb Sciences Presenting COVID-Related Cytokine Release Syndrome Results at H.C. Wainwright's 23rd Annual Global Investment Conference

Highlighting Gb Sciences' Development of Plant-Inspired Therapies for COVID-related Cytokine Release Syndrome, Chronic Pain, and Parkinson's Disease during the Healthcare & Biotech Track starting Mond...

2 years ago - GlobeNewsWire

Gb Sciences to Present at the SNN Network Summer Virtual Event on Wednesday, August 18th, 2021

LAS VEGAS, NV / ACCESSWIRE / August 10, 2021 / Gb Sciences (OTCQB:GBLX), a plant-based research and biopharmaceutical drug development company, today announced that it will be presenting at the SNN Ne...

2 years ago - Accesswire

GB Sciences Is Developing Plant-Inspired Mixtures for Anxiety, Depression, and Pain From PhAROS, GB Sciences' Proprietary AI-Accelerated Drug Discovery Platform

GB Sciences used PhAROS™, their novel AI-accelerated drug discovery platform, to identify and pre-validate optimized therapeutic mixtures for the treatment of anxiety, depression, and pain from mixtur...

2 years ago - Accesswire

GB Sciences Using AI Technology in Plant-Based Drug Discovery Research

Biotech innovator GB Sciences has launched a drug discovery platform using AI technology that can identify and predict the efficacy of combinations of novel active ingredients from plants. LAS VEGAS, ...

3 years ago - Accesswire